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Objectives: Electronic medical records (EMR) are increasingly utilized in clini-
cal practice and research, allowing for more efficient availability of rich patient 
records. However, most use of EMR is limited to coded, structured, and adminis-
trative data, while the vast majority of patient information (e.g. disease subtype, 
severity, medical device usage, etc.) is tied up in narrative clinical notes. The chal-
lenge remains in accessing the information in these patient notes. Historically 
this has been done via timely and costly manual chart review, but as the amount 
of EHR data increases exponentially, manual chart review becomes impractical 
and impossible. Advancements in Natural Language Processing (NLP) have dem-
onstrated promising results in combining the capture of additional clinical note 
information with the efficiency of modern informatics. The objective of this study 
is to demonstrate the relevancy and utility of NLP to extract health data from 
EMR in real-world observational studies. MethOds: We conducted a systematic 
review and meta analysis of performance metrics for five (5) NLP-driven projects 
involving oncology, inflammation and medical devices ,which had similar proto-
cols and objectives. We assessed and validated the accuracy of NLP algorithms, 
as well as heterogeneity of accuracy between studies using random effects meta-
analysis (represented by I2 value). Results: A total of 382,523 patients were 
identified using NLP among the 5 studies. Accuracy among the studies ranged 
from 95.2% to 100% (95% CI: 95.1%, 100%), with an I2 value of 95.9% (95% CI: 92.9%, 
97.7%). cOnclusiOns: NLP provide a unique opportunity to extract meaningful 
information from patient-level narrative clinical notes in EMR data sources with 
high degree of accuracy. This provides additional rich sources of data from narra-
tive clinical notes, that are otherwise not easily available, to support epidemiology 
and other real-world observational studies.
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Objectives: Regarding compliance analysis numerous ratios can be found in 
international scientific literature with simpler or more complex methodology. In 
our analysis we tend to reveal, that choosing an adequate ratio is not sufficient 
itself, it is essential to know the difficulties and pitfalls of the data management 
and methodology to the objective assessment of the chosen ratio. The chief aim 
of our study to demonstrate factors in course of practical examples, which may 
substantially influence the results and the right conclusions, if these factors are 
modified. MethOds: The analysis is based on prescription refilling’s data of 
database of the Hungarian Health Fund in the field of the following indications: 
diabetes, COPD, oncology. From the ratios available in scientific literature, the PDC 
(Proportion of Days Covered) was chosen. The following aspects were considered 
as influencing factors: patient inclusion criteria (index date, time frame, criteria 
of refillings); DDD (WHO, SPC or real-world dosage to DOT); Gap (period without 
medication supply). A basic setting was established to calculate PDC ratio, then 
after changing each above specified parameters one by one (ceteris paribus), the 
ratio was recalculated. Results: The PDC ratio shows huge variability recalcu-
lated by the different values of each parameters. Even more than 20% difference 
can be observed after modifying the gap (strict 1-day or permissive 30-day), or 
applying the SPC dosage instead of WHO DDD. In course of modifying the patient 
inclusion criteria both patient numbers and the ratio also show significant differ-
ences. cOnclusiOns: Based on the results it may be concluded, that no general 
best practice can be observed, all settings have both advantages and limitations. 
It may be worth choosing the key parameters considering the specialties of each 
indications in order to draw conclusions as correct as possible with the focus of 
the original aim of the study.
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Objectives: Generic comorbidity measures developed to predict mortality and/
or healthcare costs are often used as adjustment covariates in observational stud-
ies comparing health expenditures between different therapeutic strategies. The 
objective of this review is to identify available measures, and assess their perfor-
mance for prediction of economic outcomes using large longitudinal patient data-
bases. MethOds: We conducted a comprehensive literature search in MEDLINE, 
until April 2015. All methodological papers describing a new comorbidity measure 
or assessing their ability to predict economic outcomes using administrative data or 
electronic medical records were selected. We search for additional studies through 
references lists of selected articles. We extracted information on the conditions 
for using each index and predictive performance. Results: 323 abstracts were 
identified during the search in MEDLINE and 25 full papers were reviewed. Eleven 
comorbidity measures and seven comparative studies were found. Four comorbid-
ity measures were single cumulative weighted scores: two were diagnosis-based 
indexes developed using large administrative health databases and two others were 
medication-based indexes developed using pharmacy data. Two comorbidity meas-
urement systems consisted in classifying patients in mutually exclusive groups 
defined based on diagnosis and clinical or economical characteristics. Others were 
simple counts of diseases. All measures were based on a list of diseases pre-selected 
by clinicians, except for the Ambulatory Clinical Groups System (ACG). Five meas-
ures were adapted for use with ICD-9-CM and ICD-10 classifications. Hierarchical 
Cost Groups (HCC-CMS) and Quality and Outcome Framework (QOF) showed the 
highest predictive ability in three comparative studies. ACG was the best predictor 
in one study and the second one in three other analyses. cOnclusiOns: HCC-
CMS and QOF were reported to have the best predictive performance. However 
most comparative studies included a limited number of comorbidity measures. 
containing at least one product and one adverse event keyword were collected, de-
identified, and standardized using a vernacular to MedDRA dictionary. Posts were 
classified as resembling an adverse event report (Proto-AEs) or simply discussing 
a product (Mention). Results: There were a total of 1,410,819 posts categorized 
as Proto-AEs, 265,838 (19%) from Facebook and 1,144,981 (81%) from Twitter. The 
top 10 products accounted for 940,666 (67%) of the total Proto-AEs in Facebook and 
Twitter combined. The top 25 accounted for 1,180,040 (84%), the top 50 for 1,285,836 
(91%), and the top 100 for 1,245,010 (95%) of the total Proto-AEs. The top 10 products 
(diphenhydramine, flu vaccine, dextroamphetamine, codeine, morphine, ibuprofen, 
alprazolam, acetaminophen, oxycodone, and zolpidem) were comprised of six con-
trolled substances, three over-the-counter (OTC) products, and one class of vaccine. 
Of the top 50 products, controlled substances accounted for 32%, OTC products for 
24%, and vaccines for 10%. cOnclusiOns: Review of publically available data over 
the past two years from two popular social media sites, Facebook and Twitter, offers 
a high number of potential adverse events (Proto-AEs) for further evaluation. Social 
listening may be potentially valuable as a supplement to traditional pharmacovigi-
lance practices, particularly for controlled substances, over-the-counter products, 
and vaccines. These initial findings warrant more research and a closer inspection 
as to the nature of these posts.
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Objectives: There are a number of search filters designed to identify studies 
with particular study designs in electronic databases. This study compared three 
filters for identifying randomised controlled trials (RCTs). MethOds: Searches 
were conducted on 15thJune 2015 in the Ovid MEDLINE and MEDLINE In-process 
databases using The Cochrane Highly Sensitive Search Strategy for Identifying 
Randomized Trials in MEDLINE, the SIGN Randomised Controlled Trials MEDLINE 
filter and the BMJ MEDLINE Randomised Controlled Trial Strategy. Differences were 
explored by reviewing samples of records uniquely identified by each filter. For 
comparison, a sample of articles returned by all three filters was also reviewed. 
To estimate the sensitivity of each filter, the detection of 39 publications of RCTs 
included in a randomly-selected Cochrane Collaboration systematic literature 
review (SLR) was tested. Results: 476,551 records were identified by all three 
filters. From a sample of 384 records, 230 were RCTs and 18 were SLRs, meta-
analyses or pooled analyses of RCTs. 1,000,716 records were uniquely identified 
by the Cochrane filter; of 400 records sampled , 0 were RCTs and 3 were SLRs 
or meta-analyses of RCTs. 500,127 articles were uniquely identified by the SIGN 
filter; of 386 records sampled, 8 were RCTs and 1 was a meta-analysis of RCTs. 
84,938 records were uniquely identified by the BMJ filter; of 400 records sampled, 
6 were RCTs and 5 were SLRs or meta-analyses of RCTs. 39/39, 38/39 and 37/39 of 
the Cochrane review publications were identified by the Cochrane, SIGN and BMJ 
filters, respectively. The publication missed by the SIGN filter was not the same as 
the 2 missed by the BMJ filter. cOnclusiOns: All filters failed to identify at least 
some RCTs, SLRs or meta-analyses of RCTs. Differences between filters, including 
the publications uniquely identified by each, should be considered when selecting 
filters for use in literature reviews.
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Objectives: OncoLitBank is a registry of published oncology trials and Health 
Technology Assessments aimed to help provide a platform for secondary data 
analytics in the field of oncology. To demonstrate the utility and functionality of 
OncoLitBank, we conducted a basic indirect treatment comparison (ITC) between 
gemcitabine/nab-paclitaxel (GemNpac) and gemcitabine/capecitabine(GemCap) 
combinations which were each tested against gemcitabine but not against 
each other for treatment of metastatic pancreatic cancer. MethOds: Using 
OncoLitBank, data for metastatic pancreatic cancer were filtered for treatment-
comparator arms of interest by using built-in interactive features. Two phase III 
randomized controlled trials (RCTs) comparing GemCap vs Gem, while 1 RCT 
comparing GemNpac vs Gem were included for the ITC. Data on overall response 
rate (ORR), 1-year survival, overall survival (OS), progression-free survival (PFS), 
and grade 3-4 adverse events (AEs) were pooled for the 2 RCTs comparing GemCap 
vs Gem using RevMan 5.0. Pooled risk ratios (RRs) and mean differences (MD) 
for the 2 studies were derived for dichotomous and continuous outcome vari-
ables respectively and compared to the single RCT that evaluated GemNpac vs 
Gem to derive the ITC RRs and MDs using the Canadian Agency for Drugs and 
Technologies in Health (CADTH) ITC application which employs Bucher et al. 
(1997) method. Results: The use of OncoLitBank was successful and eliminated 
the need to conduct a new systematic review to perform the ITC leading to a 
quick turn-around of tasks at hand. Results demonstrated that GemNpac was 
not superior to GemCap in ORR, 1-year survival, OS, PFS and grade 3-4 AEs, as 
no significant differences was detected. cOnclusiOns: OncoLitBank provides 
users with a robust data platform that can be easily used for systematic reviews, 
conduct meta-analyses through direct orindirect comparisons, inform economic 
models, landscape analyses, value dossiers, create target product profiles and 
value development plans.
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